

Jacques Genest jr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8257850/publications.pdf>

Version: 2024-02-01

109
papers

19,794
citations

66234

42
h-index

30010

103
g-index

110
all docs

110
docs citations

110
times ranked

23474
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1119-1131.	13.9	6,227
2	Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. <i>New England Journal of Medicine</i> , 2008, 359, 2195-2207.	13.9	5,712
3	Effect of interleukin-1 β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2017, 390, 1833-1842.	6.3	948
4	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1263-1282.	0.8	775
5	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. <i>Lancet, The</i> , 2018, 391, 319-328.	6.3	628
6	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1129-1150.	0.8	367
7	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. <i>Lancet Diabetes and Endocrinology, the</i> , 2016, 4, 850-861.	5.5	329
8	Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1742-1759.	1.6	301
9	Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. <i>Atherosclerosis</i> , 2018, 276, 98-108.	0.4	289
10	Common Genetic Variation in <i>ABCA1</i> Is Associated With Altered Lipoprotein Levels and a Modified Risk for Coronary Artery Disease. <i>Circulation</i> , 2001, 103, 1198-1205.	1.6	280
11	Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. <i>BMJ Open</i> , 2017, 7, e016461.	0.8	244
12	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. <i>Lancet, The</i> , 2010, 376, 333-339.	6.3	221
13	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). <i>Canadian Journal of Cardiology</i> , 2016, 32, S35-S65.	0.8	194
14	High-Density Lipoproteins and Endothelial Function. <i>Circulation</i> , 2001, 104, 1978-1983.	1.6	183
15	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.	0.4	163
16	Homocysteine β betaine interactions in a murine model of 5,10 α -methylene tetrahydrofolate reductase deficiency. <i>FASEB Journal</i> , 2003, 17, 1-25.	0.2	147
17	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet, The</i> , 2021, 398, 1713-1725.	6.3	142
18	High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk. <i>BBA Clinical</i> , 2015, 3, 175-188.	4.1	140

#	ARTICLE	IF	CITATIONS
19	Aortic calcification: Novel insights from familial hypercholesterolemia and potential role for the low-density lipoprotein receptor. <i>Atherosclerosis</i> , 2013, 226, 9-15.	0.4	130
20	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1553-1563.	0.8	105
21	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1471-1481.	0.8	93
22	Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. <i>Cmaj</i> , 2003, 169, 921-4.	0.9	87
23	C-reactive protein: Risk factor, biomarker and/or therapeutic target?. <i>Canadian Journal of Cardiology</i> , 2010, 26, 41A-44A.	0.8	85
24	APOE p.Leu167del mutation in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2013, 231, 218-222.	0.4	84
25	HDL, Atherosclerosis, and Emerging Therapies. <i>Cholesterol</i> , 2013, 2013, 1-18.	1.6	70
26	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. <i>Lancet</i> , 2022, 399, 719-728.	6.3	69
27	Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. <i>Circulation</i> , 2017, 135, 1819-1831.	1.6	67
28	Biogenesis and speciation of nascent apoA-I-containing particles in various cell lines. <i>Journal of Lipid Research</i> , 2005, 46, 1668-1677.	2.0	64
29	Lipoprotein(a) Induces Human Aortic Valve Interstitial Cell Calcification. <i>JACC Basic To Translational Science</i> , 2017, 2, 358-371.	1.9	63
30	Simplified Canadian Definition for Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1210-1214.	0.8	62
31	Long-Term Effects of 4 Popular Diets on Weight Loss and Cardiovascular Risk Factors. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 815-827.	0.9	60
32	The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography. <i>Atherosclerosis</i> , 2011, 219, 455-462.	0.4	54
33	Quantitative Analysis of ABCA1-dependent Compartmentalization and Trafficking of Apolipoprotein A-I. <i>Journal of Biological Chemistry</i> , 2008, 283, 11164-11175.	1.6	53
34	High-Density Lipoprotein Mediated Cellular Cholesterol Efflux in Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2014, 113, 249-255.	0.7	51
35	Plasma homocysteine concentration in children with chronic renal failure. <i>Pediatric Nephrology</i> , 2001, 16, 805-811.	0.9	49
36	The <i>WWOX</i> Gene Modulates High-Density Lipoprotein and Lipid Metabolism. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 491-504.	5.1	49

#	ARTICLE	IF	CITATIONS
37	Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. <i>American Journal of Cardiology</i> , 2004, 93, 848-853.	0.7	48
38	Novel Apo E-Derived ABCA1 Agonist Peptide (CS-6253) Promotes Reverse Cholesterol Transport and Induces Formation of pre β -1 HDL In Vitro. <i>PLoS ONE</i> , 2015, 10, e0131997.	1.1	48
39	Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2019, 13, 15-30.	0.6	48
40	Prevention of Cardiovascular Ischemic Events. <i>Circulation</i> , 2003, 107, 2059-2065.	1.6	47
41	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. <i>Clinical Chemistry</i> , 2018, 64, 355-362.	1.5	47
42	ATP binding cassette A1 (ABCA1) mediates microparticle formation during high-density lipoprotein (HDL) biogenesis. <i>Atherosclerosis</i> , 2017, 257, 90-99.	0.4	46
43	Reducing Vascular Calcification by Anti-IL-1 β Monoclonal Antibody in a Mouse Model of Familial Hypercholesterolemia. <i>Angiology</i> , 2016, 67, 157-167.	0.8	44
44	HDL cholesterol and ASCVD risk stratification: A debate. <i>Atherosclerosis</i> , 2019, 283, 7-12.	0.4	43
45	Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2632-2640.	1.1	42
46	High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management. <i>Canadian Journal of Cardiology</i> , 2017, 33, 325-333.	0.8	41
47	Genetic testing for familial hypercholesterolemia: Impact on diagnosis, treatment and cardiovascular risk. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1262-1270.	0.8	38
48	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): Lessons Learned from Patients with Hypercholesterolemia. <i>Clinical Chemistry</i> , 2014, 60, 1380-1389.	1.5	32
49	Aortic calcifications in familial hypercholesterolemia: Potential role of the low-density lipoprotein receptor gene. <i>American Heart Journal</i> , 2009, 157, 170-176.	1.2	30
50	Membrane microdomains modulate oligomeric ABCA1 function: impact on apoAI-mediated lipid removal and phosphatidylcholine biosynthesis. <i>Journal of Lipid Research</i> , 2011, 52, 2043-2055.	2.0	30
51	Apolipoprotein E derived HDL mimetic peptide ATI-5261 promotes nascent HDL formation and reverse cholesterol transport in vitro. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2014, 1841, 1498-1512.	1.2	25
52	Familial hypercholesterolemia: experience from the French-Canadian population. <i>Current Opinion in Lipidology</i> , 2018, 29, 59-64.	1.2	25
53	Familial hypercholesterolemia. Acceptor splice site (G \rightarrow C) mutation in intron 7 of the LDL-R gene: alternate RNA editing causes exon 8 skipping or a premature stop codon in exon 8. LDL-R Honduras-1 [LDL-R1061(G \rightarrow C)]. <i>Atherosclerosis</i> , 1999, 146, 125-131.	0.4	24
54	Severe xanthomatosis in heterozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2018, 12, 872-877.	0.6	24

#	ARTICLE	IF	CITATIONS
55	Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2019, 13, 123-128.	0.6	24
56	Risk of Ischemic Stroke and Peripheral Arterial Disease in Heterozygous Familial Hypercholesterolemia: A Meta-Analysis. <i>Angiology</i> , 2019, 70, 726-736.	0.8	23
57	Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come?. <i>Clinical Chemistry</i> , 2016, 62, 428-435.	1.5	22
58	Estrogen-associated severe hypertriglyceridemia with pancreatitis. <i>Journal of Clinical Lipidology</i> , 2017, 11, 297-300.	0.6	21
59	Desmocollin 1 is abundantly expressed in atherosclerosis and impairs high-density lipoprotein biogenesis. <i>European Heart Journal</i> , 2018, 39, 1194-1202.	1.0	21
60	No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. <i>Atherosclerosis</i> , 2020, 311, 13-19.	0.4	21
61	Pathological significance of lipoprotein(a) in aortic valve stenosis. <i>Atherosclerosis</i> , 2018, 272, 168-174.	0.4	20
62	Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. <i>Canadian Journal of Cardiology</i> , 2006, 22, 863-868.	0.8	19
63	Approach to the diagnosis and management of lipoprotein disorders. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2009, 16, 132-140.	1.2	19
64	HDLs and the pathogenesis of atherosclerosis. <i>Current Opinion in Cardiology</i> , 2018, 33, 311-316.	0.8	19
65	Genetics and Prevention: A New Look at High-Density Lipoprotein Cholesterol. <i>Cardiology in Review</i> , 2002, 10, 61-71.	0.6	18
66	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. <i>Atherosclerosis</i> , 2018, 277, 419-424.	0.4	18
67	Genetics of Cholesterol Efflux. <i>Current Atherosclerosis Reports</i> , 2012, 14, 235-246.	2.0	17
68	Circulating levels of the vasoactive peptide urotensin II in patients with acute coronary syndrome and stable coronary artery disease. <i>Peptides</i> , 2014, 55, 151-157.	1.2	17
69	Anxiety, depression, and health-related quality of life in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. <i>Journal of Psychosomatic Research</i> , 2018, 109, 32-43.	1.2	16
70	Aortic Calcification Progression in Heterozygote Familial Hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , 2017, 33, 658-665.	0.8	15
71	Evidence for improved survival with treatment of homozygous familial hypercholesterolemia. <i>Current Opinion in Lipidology</i> , 2020, 31, 176-181.	1.2	15
72	High-density lipoproteins: multifunctional vanguards of the cardiovascular system. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 417-430.	0.6	14

#	ARTICLE	IF	CITATIONS
73	ABCA1 Agonist Mimetic Peptide CS-6253 Induces Microparticles Release From Different Cell Types by ABCA1-Efflux-Dependent Mechanism. <i>Canadian Journal of Cardiology</i> , 2019, 35, 770-781.	0.8	14
74	Monoclonal Antibodies for the Treatment of Hypercholesterolemia: Targeting PCSK9. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1552-1560.	0.8	13
75	Treatment options for low high-density lipoproteins. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2014, 21, 134-139.	1.2	12
76	Membrane microdomains and the regulation of HDL biogenesis. <i>Current Opinion in Lipidology</i> , 2018, 29, 36-41.	1.2	12
77	Lomitapide for treatment of homozygous familial hypercholesterolemia: The Québec experience. <i>Atherosclerosis</i> , 2020, 310, 54-63.	0.4	12
78	HDL-Mediated Cellular Cholesterol Efflux Assay Method. <i>Annals of Clinical and Laboratory Science</i> , 2015, 45, 659-68.	0.2	12
79	Sex Differences in the Presentation, Treatment, and Outcome of Patients With Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , 2021, 10, e019286.	1.6	11
80	Apolipoprotein A-I Truncations in Chagas Disease Are Caused by Cruzipain, the Major Cysteine Protease of <i>Trypanosoma cruzi</i> . <i>American Journal of Pathology</i> , 2014, 184, 976-984.	1.9	10
81	Novel Approaches for HDL-Directed Therapies. <i>Current Atherosclerosis Reports</i> , 2017, 19, 55.	2.0	10
82	Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1027-1038.	0.6	10
83	Health-related quality of life in homozygous familial hypercholesterolemia: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2022, 16, 52-65.	0.6	8
84	Influence of the LDL-Receptor Genotype on Statin Response in Heterozygous Familial Hypercholesterolemia: Insights From the Canadian FH Registry. <i>Canadian Journal of Cardiology</i> , 2022, 38, 311-319.	0.8	7
85	New Strategies to Promote Macrophage Cholesterol Efflux. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 795868.	1.1	7
86	Identification of Docetaxel as a Potential Drug to Promote HDL Biogenesis. <i>Frontiers in Pharmacology</i> , 2021, 12, 679456.	1.6	6
87	Familial Hypercholesterolemia: Awareness, Appraisal, and Action. <i>Canadian Journal of Cardiology</i> , 2017, 33, 298-299.	0.8	5
88	The analysis by Manuel and colleagues creates controversy with headlines, not data. <i>Cmaj</i> , 2005, 172, 1033-1034.	0.9	4
89	High-Density Lipoprotein and Residual Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1842-1844.	1.2	4
90	Severe hyperhomocysteinemia due to cystathionine β -synthase deficiency, and Factor V Leiden mutation in a patient with recurrent venous thrombosis. <i>Thrombosis Journal</i> , 2014, 12, 30.	0.9	4

#	ARTICLE	IF	CITATIONS
91	The Lifelong Burden of Homozygous Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2019, 35, 1419.e1-1419.e4.	0.8	4
92	Macrophage Jak2 deficiency accelerates atherosclerosis through defects in cholesterol efflux. Communications Biology, 2022, 5, 132.	2.0	4
93	Disorders of high-density lipoprotein biogenesis. Annals of Medicine, 2008, 40, 39-47.	1.5	2
94	Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm. CJC Open, 2019, 1, 190-197.	0.7	2
95	Dj1 deficiency protects against atherosclerosis with anti-inflammatory response in macrophages. Scientific Reports, 2021, 11, 4723.	1.6	2
96	Abstract 1696: Compound RVX-208 Modulates HDL-C Levels and Function in Non-human Primates and in Early (phase I) Human Trials. Circulation, 2008, 118, .	1.6	2
97	Abstract 28: Adiponectin Stimulates Cholesterol Efflux Efficiently in Human THP-1 Macrophages and Modulates HDL-apoA-I Biogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, .	1.1	2
98	Prevalence and Treatment of Familial Hypercholesterolemia and Severe Hypercholesterolemia in Older Adults in Ontario, Canada. CJC Open, 2022, 4, 739-747.	0.7	2
99	High-Density Lipoprotein and Cardiovascular Disease—Where do We Stand?. Endocrinology and Metabolism Clinics of North America, 2022, , .	1.2	2
100	Access Denied: The Controversy of Commercial Genetic Databases. Canadian Journal of Cardiology, 2016, 32, 1295-1296.	0.8	1
101	Smashing Low-Density Lipoprotein Levels and Preventing Coronary Allograft Vasculopathy: One Heart Transplant Patient at a Time. Canadian Journal of Cardiology, 2019, 35, 17-18.	0.8	1
102	High-Density Lipoproteins and Inflammatory Diseases: Full Circle Ahead. Clinical Chemistry, 2019, 65, 607-608.	1.5	1
103	Chylomicrons: When you can't direct the wind, adjust the sail. Atherosclerosis, 2019, 283, 121-123.	0.4	1
104	How the Cow Ate the CABG. Journal of the American College of Cardiology, 2019, 74, 1187-1189.	1.2	0
105	Abstract 14: The Anti-atherosclerosis ABCA1 Agonist CS6253 Confer Glucose Control by Improved Pancreas Beta-cell Insulin Secretion and Enhanced Peripheral Insulin Utility. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, .	1.1	0
106	The Essential Role of Primary Caregiver in Early Detection of Familial Hypercholesterolemia and Cardiovascular Prevention. Current Pediatric Reviews, 2018, 13, 260-264.	0.4	0
107	The Cholesterol Uptake Capacity: The search for scalable HDL function tests continues. Atherosclerosis, 2022, 345, 39-40.	0.4	0
108	Novel insights on high-density lipoprotein in coronary heart disease. International Journal of Clinical Practice, Supplement, 2002, , 17-22.	0.3	0

#	ARTICLE	IF	CITATIONS
109	Preventive cardiology: move over low density lipoprotein cholesterol, hello C-reactive protein? Canadian Journal of Cardiology, 2004, 20 Suppl B, 89B-92B.	0.8	0